P2‐069: INTRANASAL DANTROLENE AS A DISEASE‐MODIFYING DRUG IN ALZHEIMER 5XFAD MICE

• DOI: 10.1016/j.jalz.2019.06.2476
• Publication Date: 2019-10-18T10:58:25Z
• Authors: Yun Shi; Lei Zhang; Xue Gao; Jing Zhang; Matan Ben-Abou; Qingcheng Meng; Adrian Hepner; Maryellen F. Ecke...; Huafeng Wei
• Keywords: Subcutaneous injection

Amyloid pathology and memory loss are significantly inhibited when treated with Dantrolene (oral or subcutaneous administration) before the onset of AD symptoms. This study compares therapeutic side effects intranasal vs administration dantrolene, after neuropathology cognitive dysfunction in 5XFAD mice. Aged-matched male female C57BL/6 (WT) mice were dantrolene (5 mg/kg, 3x/wk), vehicle. An early treatment group (ETG) received from 2–11 months age late (LTG) 6–11 age. Olfaction (buried food test), motor function (rotarod), (fear conditioning), liver histology (H&E) (plasma ALT levels), brain amyloid immunohistochemistry biochemistry assessed. N=9-18/group. Both subcutaneously administered improved hippocampal-dependent -independent ETG, whereas only cognition LTG. No significant detected mortality, olfaction, function. had no change burden 5xFAD Intranasal provided better on than administration, especially was started accumulation dysfunction.